Bulent Ozpolat

TL;DR: These guidelines are presented for the selection and interpretation of methods for use by investigators who aim to examine macroautophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.

TL;DR: The data suggest that, depending on the cellular features, either the induction or the inhibition of autophagy can provide therapeutic benefits to patients and that the design and synthesis of the first-generation modulators of Autophagy may provide the tools for proof of concept experiments and the impetus for translational studies that may ultimately lead to new therapeutic strategies in cancer.

TL;DR: The development of siRNAs as therapeutic agents from early design to clinical trial is reviewed, with special emphasis on the development of EphA2-targeting si RNAs for ovarian cancer treatment.

TL;DR: A highly safe and effective neutral lipid-based nanoliposomes that provide robust gene silencing in tumors following systemic (intravenous) administration is developed and demonstrated remarkable antitumor efficacy in various orthotopic human cancer models in animals.

TL;DR: The role of Bcl-2 in autophagy in breast cancer cells is investigated and silencing of B cl-2 by siRNA led to induction of LC-3-II, a hallmark ofAutophagy, ATG5 and Beclin-1 autophile promoting proteins.